Who is sponsoring NCT00623974?

NCT00623974 is sponsored by M.D. Anderson Cancer Center.

What condition does NCT00623974 study?

NCT00623974 studies Hypocalcemia.

What drugs are being tested in NCT00623974?

Interventions: Teriparatide (Forteo), Calcium, Calcitriol.

What is the status of NCT00623974?

NCT00623974 is currently TERMINATED.

Last reviewed 2012-12-04 · How we verify

A Phase II Study of Short-Term Use of Teriparatide (Forteo) in the Treatment of Patients With Postoperative Hypocalcemia

NCT00623974 Phase 2 TERMINATED Results posted

Primary Objective: -To identify the optimal dose of a seven-day course of twice-daily teriparatide as compared to standard therapy for hypocalcemia in patients after total thyroidectomy and/or extensive neck dissections (pharyngectomy, laryngectomy,unilateral, bilateral / central neck, mediastinal lymph node neck dissections), with which serum calcium will be raised to corrected serum calcium levels of 8-10.5mg/dL and maintained within this range until the end of the treatment course.

Details

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	TERMINATED
Enrolment	7
Start date	2008-05
Completion	2010-06

Conditions

Hypocalcemia

Interventions

Teriparatide (Forteo)
Calcium
Calcitriol

Primary outcomes

Number of Patients With Success — 2 - 7 days post-treatment
A patient "success" is defined as a normal calcium level (Ca\>=8 and Ca\<= 10.5) within 48 hours post-treatment initiation and a normal Ca level maintained through day 7 post-treatment initiation.

Countries

United States